“We believe this novel anticoagulation approach could be a meaningful step forward from current standard-of-care, the widely used DOAC class (Eliquis, Xarelto etc).” Bayer had a factor XIa ...
Drugs covered include the widely used diabetes treatments Januvia and Jardiance, blood thinners Eliquis and Xarelto and leukaemia drug Imbruvica. Junuvia faces the steepest price reduction ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback